American Renal Associates Holdings, Inc (NYSE:ARA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm currently has a $20.00 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 9.11% from the stock’s current price.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, Wells Fargo & Company raised shares of American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $25.50.

American Renal Associates Holdings (ARA) traded up 3.74% during midday trading on Tuesday, reaching $18.33. 261,820 shares of the company’s stock traded hands. The company’s market capitalization is $571.00 million. The firm’s 50 day moving average price is $17.49 and its 200-day moving average price is $19.01. American Renal Associates Holdings has a 1-year low of $15.47 and a 1-year high of $28.53.

American Renal Associates Holdings (NYSE:ARA) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.04. American Renal Associates Holdings had a negative net margin of 2.13% and a positive return on equity of 20.97%. The business had revenue of $177 million during the quarter, compared to analysts’ expectations of $184.67 million. During the same period last year, the company earned $0.16 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. Equities analysts expect that American Renal Associates Holdings will post $0.50 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “American Renal Associates Holdings, Inc (NYSE:ARA) Lifted to Buy at Zacks Investment Research” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/american-renal-associates-holdings-inc-nyseara-lifted-to-buy-at-zacks-investment-research.html.

Institutional investors have recently added to or reduced their stakes in the stock. Atria Investments LLC raised its position in American Renal Associates Holdings by 2.2% in the second quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock worth $203,000 after buying an additional 233 shares in the last quarter. Geode Capital Management LLC raised its position in American Renal Associates Holdings by 2.9% in the first quarter. Geode Capital Management LLC now owns 77,726 shares of the company’s stock worth $1,312,000 after buying an additional 2,180 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in American Renal Associates Holdings by 7.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 38,847 shares of the company’s stock worth $656,000 after buying an additional 2,565 shares in the last quarter. Bank of America Corp DE raised its position in American Renal Associates Holdings by 21.6% in the first quarter. Bank of America Corp DE now owns 29,837 shares of the company’s stock worth $504,000 after buying an additional 5,296 shares in the last quarter. Finally, Teachers Advisors LLC raised its position in American Renal Associates Holdings by 42.6% in the fourth quarter. Teachers Advisors LLC now owns 20,092 shares of the company’s stock worth $428,000 after buying an additional 6,000 shares in the last quarter. 87.58% of the stock is currently owned by institutional investors.

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Get a free copy of the Zacks research report on American Renal Associates Holdings (ARA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for American Renal Associates Holdings (NYSE:ARA)

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.